Evidence map›Paper›PMID 30723701›Full record

ArticleFrontiers in oncology2019

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study).

Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sadamoto ZendaDepartment of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yosuke OtaDepartment of Radiation Oncology, Hyogo Cancer Center Hospital, Hyogo, Japan.
Naomi KiyotaDepartment of Medical Oncology, Cancer Center, Kobe University Hospital, Kobe, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Masato FujiiDepartment of Otolaryngology, Tokyo Medical Center, Tokyo, Japan.
Morimasa KitamuraDepartment of Otolaryngology, Head and Neck Surgery, Kyoto University Hospital, Kyoto, Japan.
Shunji TakahashiDepartment of Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Tsutomu UedaDepartment of Otorhinolaryngology-Head and Neck Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Nobuya MondenDepartment of Head and Neck Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Takeharu YamanakaDepartment of Biostatistics and Epidemiology, Yokohama City University School of Medicine, Yokohama, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cetuximabclinical trialendpointhead and neck cancerinduction chemotherapy

Identifiers

PMID30723701
PMCPMC6349830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.